| Michael James Keller, MD | |
|
800 Biesterfield Rd, Suite 510, Elk Grove Village, IL 60007-3361 | |
| (847) 981-3660 | |
| (847) 956-5108 |
| Full Name | Michael James Keller |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 18 Years |
| Location | 800 Biesterfield Rd, Elk Grove Village, Illinois |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013164086 | NPI | - | NPPES |
| 036134102 | Medicaid | IL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 036123136 (Illinois) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 036123136 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Alexian Brothers Medical Center 1 | Elk grove village, IL | Hospital |
| St Alexius Medical Center | Hoffman estates, IL | Hospital |
| Northwest Community Hospital 1 | Arlington heights, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alexian Brothers Medical Care Group Nfp | 6002134624 | 47 |
News Archive
Scientists from the Queen's University, Canada, have recently uncovered the broad-spectrum antiviral activity of epigallocatechin gallate, a bioactive compound from green tea, against highly pathogenic coronaviruses found in humans and animals. The compound prevents viral infection by interfering with virus-host cell attachment. The study is currently available on the bioRxiv* preprint server.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today that it has completed, two months ahead of schedule, enrolment in the first stage of its pivotal Phase II/III trial of C-Cure, a unique stem cell therapy for heart failure.
An international team of scientists from Nanyang Technological University, Singapore (NTU Singapore), Brown University and the Massachusetts Institute of Technology (MIT) has developed an artificial intelligence (AI) platform that could one day be used in a system to assess vascular diseases, which are characterised by the abnormal condition of blood vessels.
Researchers in Melbourne, Australia, have found that even our immune system is subject to performance enhancement, with our bodies giving immune cells the boost they need to ensure the best team is selected to fight infections.
Drug delivery company pSivida Corp today announced it amended and restated its Research and Development Agreement with Pfizer Inc. to focus solely on the development of a long-term, sustained-release implant to deliver latanoprost for patients with ocular hypertension and glaucoma.
› Verified 7 days ago
| Entity Name | Alexian Brothers Specialty Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720371669 PECOS PAC ID: 0840465084 Enrollment ID: O20111216000081 |
News Archive
Scientists from the Queen's University, Canada, have recently uncovered the broad-spectrum antiviral activity of epigallocatechin gallate, a bioactive compound from green tea, against highly pathogenic coronaviruses found in humans and animals. The compound prevents viral infection by interfering with virus-host cell attachment. The study is currently available on the bioRxiv* preprint server.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today that it has completed, two months ahead of schedule, enrolment in the first stage of its pivotal Phase II/III trial of C-Cure, a unique stem cell therapy for heart failure.
An international team of scientists from Nanyang Technological University, Singapore (NTU Singapore), Brown University and the Massachusetts Institute of Technology (MIT) has developed an artificial intelligence (AI) platform that could one day be used in a system to assess vascular diseases, which are characterised by the abnormal condition of blood vessels.
Researchers in Melbourne, Australia, have found that even our immune system is subject to performance enhancement, with our bodies giving immune cells the boost they need to ensure the best team is selected to fight infections.
Drug delivery company pSivida Corp today announced it amended and restated its Research and Development Agreement with Pfizer Inc. to focus solely on the development of a long-term, sustained-release implant to deliver latanoprost for patients with ocular hypertension and glaucoma.
› Verified 7 days ago
| Entity Name | Alexian Brothers Medical Care Group Nfp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518420413 PECOS PAC ID: 6002134624 Enrollment ID: O20150410002237 |
News Archive
Scientists from the Queen's University, Canada, have recently uncovered the broad-spectrum antiviral activity of epigallocatechin gallate, a bioactive compound from green tea, against highly pathogenic coronaviruses found in humans and animals. The compound prevents viral infection by interfering with virus-host cell attachment. The study is currently available on the bioRxiv* preprint server.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today that it has completed, two months ahead of schedule, enrolment in the first stage of its pivotal Phase II/III trial of C-Cure, a unique stem cell therapy for heart failure.
An international team of scientists from Nanyang Technological University, Singapore (NTU Singapore), Brown University and the Massachusetts Institute of Technology (MIT) has developed an artificial intelligence (AI) platform that could one day be used in a system to assess vascular diseases, which are characterised by the abnormal condition of blood vessels.
Researchers in Melbourne, Australia, have found that even our immune system is subject to performance enhancement, with our bodies giving immune cells the boost they need to ensure the best team is selected to fight infections.
Drug delivery company pSivida Corp today announced it amended and restated its Research and Development Agreement with Pfizer Inc. to focus solely on the development of a long-term, sustained-release implant to deliver latanoprost for patients with ocular hypertension and glaucoma.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael James Keller, MD 1269 N Wolcott Ave Apt 2r, Chicago, IL 60622-3895 Ph: (319) 400-1305 | Michael James Keller, MD 800 Biesterfield Rd, Suite 510, Elk Grove Village, IL 60007-3361 Ph: (847) 981-3660 |
News Archive
Scientists from the Queen's University, Canada, have recently uncovered the broad-spectrum antiviral activity of epigallocatechin gallate, a bioactive compound from green tea, against highly pathogenic coronaviruses found in humans and animals. The compound prevents viral infection by interfering with virus-host cell attachment. The study is currently available on the bioRxiv* preprint server.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today that it has completed, two months ahead of schedule, enrolment in the first stage of its pivotal Phase II/III trial of C-Cure, a unique stem cell therapy for heart failure.
An international team of scientists from Nanyang Technological University, Singapore (NTU Singapore), Brown University and the Massachusetts Institute of Technology (MIT) has developed an artificial intelligence (AI) platform that could one day be used in a system to assess vascular diseases, which are characterised by the abnormal condition of blood vessels.
Researchers in Melbourne, Australia, have found that even our immune system is subject to performance enhancement, with our bodies giving immune cells the boost they need to ensure the best team is selected to fight infections.
Drug delivery company pSivida Corp today announced it amended and restated its Research and Development Agreement with Pfizer Inc. to focus solely on the development of a long-term, sustained-release implant to deliver latanoprost for patients with ocular hypertension and glaucoma.
› Verified 7 days ago
Dr. Barry Glick, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 810 Biesterfield Rd, Suite 306, Elk Grove Village, IL 60007 Phone: 847-981-6061 Fax: 847-981-6062 | |
Dr. Bhupinder K Chhabra, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Biesterfield Rd, Suite 3007, Elk Grove Village, IL 60007 Phone: 847-290-6513 Fax: 847-290-8505 | |
Anshul Aggarwal, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Biesterfield Rd Ste G01, Elk Grove Village, IL 60007 Phone: 847-981-3680 | |
Edward J Diamond, M.D. Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 800 Biesterfield Rd, Suite 510, Elk Grove Village, IL 60007 Phone: 847-981-3660 Fax: 847-956-5108 | |
Anurag Mehrotra, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Biesterfield Rd Ste 510, Elk Grove Village, IL 60007 Phone: 847-981-3660 | |
Nephtali Kogan, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Biesterfield Rd Ste G01, Elk Grove Village, IL 60007 Phone: 847-981-3680 |